Pancreatic Cancer Clinical Trials in Illinois

Showing 121-140 of 146 trials

Gemcitabine With or Without Dalteparin in Treating Patients With Unresectable or Metastatic Pancreatic Cancer

NCT00031837

RATIONALE: Drugs used in chemotherapy, such as gemcitabine, work in different ways to stop tumor cells from dividing so they stop growing or die. Anticoagulants such as dalteparin may help prevent blood clots in patients being treated with gemcitabine for unresectable or metastatic pancreatic cancer. PURPOSE: Randomized phase III trial to compare the effectiveness of gemcitabine with or without dalteparin in treating patients who have unresectable or metastatic pancreatic cancer.

Pancreatic CancerThromboembolism

Gary Morrow400 participantsStarted Oct 2002

Mobile, Alabama, United States • Denver, Colorado, United States • Chicago, Illinois, United States +10 more locations

COMPLETEDPhase 235 miles

BMS-247550 in Treating Patients With Advanced Pancreatic Cancer

NCT00016965

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of BMS-247550 in treating patients who have advanced pancreatic cancer.

Pancreatic Cancer

SWOG Cancer Research NetworkStarted Jul 2001

Mobile, Alabama, United States • Phoenix, Arizona, United States • Phoenix, Arizona, United States +92 more locations

Gemcitabine With or Without Dalteparin in Treating Patients With Unresectable or Metastatic Pancreatic Cancer

BMS-247550 in Treating Patients With Advanced Pancreatic Cancer

Pancreatic Cancer Trials in Other Cities

Gemcitabine With or Without Oxaliplatin in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer

Radiation Therapy Plus Paclitaxel in Treating Patients With Nonmetastatic, Unresectable Pancreatic Cancer

APRiCOT-P: Study of Apricoxib With Gemcitabine and Erlotinib to Treat Advanced Pancreatic Cancer

A Study of TNFerade™ Biologic With 5-FU and Radiation Therapy for First-Line Treatment of Unresectable Locally Advanced Pancreatic Cancer

Phase II Study of Brivanib (BMS-582664) to Treat Multiple Tumor Types

3-AP and Gemcitabine in Treating Patients With Unresectable or Metastatic Pancreatic Cancer

Pancreatic Cancer Serum and DNA Repository

Paclitaxel in Treating Patients With Unresectable Locally Advanced or Metastatic Pancreatic Cancer

Triacetyluridine and Fluorouracil Compared With Gemcitabine in Treating Patients With Unresectable Locally Advanced, or Metastatic Pancreatic Cancer

Phase II Study to Evaluate Efficacy and Safety of RP101 in Combination With Gemcitabine

Ganitumab and Gemcitabine Hydrochloride Followed by Radiation Therapy, Ganitumab, Capecitabine, and Maintenance Therapy in Treating Patients With Locally Advanced Cancer of the Pancreas

Gemcitabine With or Without CI-994 in Treating Patients With Advanced Pancreatic Cancer

AZD6244 vs. Capecitabine (Xeloda®) in Patients With Advanced or Metastatic Pancreatic Cancer, Who Have Failed First Line Gemcitabine Therapy

A Study of ARRY-334543 and Gemcitabine in Patients With Advanced Cancer and Pancreatic Cancer

A Dose-Escalation to Rash Study of Tarceva (Erlotinib) Plus Gemcitabine in Patients With Metastatic Pancreatic Cancer

Gamma Secretase Inhibitor RO4929097 in Previously Treated Metastatic Pancreas Cancer

R115777 in Treating Patients Who Have Metastatic Pancreatic Cancer

Monoclonal Antibody ABX-EGF in Treating Patients With Renal (Kidney), Prostate, Pancreatic, Non-Small Cell Lung, Colon or Rectal, Esophageal, or Gastroesophageal Junction Cancer

Other Conditions in Illinois